Kazia Therapeutics Limited has entered into an At the Market Offering Agreement with Rodman & Renshaw LLC, allowing the company to offer and sell American Depositary Shares (ADSs) through Rodman as a sales agent. Each ADS represents 500 ordinary shares of the company. The offering will be made under Kazia's shelf registration statement on Form F-3, which was declared effective by the Securities and Exchange Commission on September 12, 2024. The company intends to use the net proceeds from this offering for general corporate purposes, including working capital, capital expenditures, research, clinical development, and potential acquisitions. Baker & McKenzie has provided a legal opinion on the validity of the ADSs and underlying ordinary shares. Kazia has also released supplemental risk factors to update its business disclosures.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.